Actualités
Séminaires

Prof. Resia PRETORIUS

Physiological Sciences Department, Faculty of Science, Stellenbosch University, South Africa.

"Where Clotting Meets Immunity: Uncovering Novel Drivers of Chronic Illnesses"

Resia Pretorius is a Distinguished Professor at Stellenbosch University (South Africa), Honorary Professor at the University of Liverpool, and founding director of Biocode Technologies. Her research focuses on how inflammation disrupts coagulation and  immune function, leading to microclots, platelet activation, and endothelial pathology across diseases including cancer, diabetes, cardiovascular disease and Long COVID. She has published over 330 papers, filed multiple patents on microclot diagnostics, and serves on global health advisory panels including the WHO.

host : Alain R. Thierry (IRCM)

FRANCOIS FUKS

Université Libre de Bruxelles

"Cancer Epigenetics : from New Mechanisms to New Therapies"

host : Laurent Le Cam (IRCM)

Professor Generoso BEVILACQUA

https://orcid.org/0000-0001-8857-2609

Department of Translational Research and New Technologies in Medicine, University of Pisa, Italy.

"Viral Origin of Breast Cancer"

hôte : Andrei TURTOI (IRCM)

Professor Kazuya KABAYAMA

Institute for Radiation Sciences, Osaka University, Japan

"Alpha-targeted therapy by regulating the intracellular dynamics of antibody drugs"

Professor Kazuya Kabayama leads the Laboratory for Radiation Chemical Biology at Osaka University, where his research bridges chemistry, cellular biology, and nuclear medicine. His primary focus is on developing innovative treatments in radiotherapy, particularly targeted alpha therapy (TAT) using astatine-211 (211At), a promising alpha-emitting radionuclide for the treatment of resistant cancers. Professor Kabayama has contributed significantly to the design and synthesis of 211At-labeled compounds aimed at first-in-human clinical trials. He has also participated in studies exploring 211At-labeled gold nanoparticles, demonstrating their potent antitumor effects. His work plays a key role in advancing the clinical translation of alpha-based radiopharmaceuticals. In parallel, his research investigates molecular interactions involving lipids and glycans, especially in the context of innate immunity and diseases such as cancer and diabetes. His team develops real-time cellular imaging tools to analyze the dynamics of glycolipids and multivalent glycan-receptor interactions at the membrane level. Through a highly interdisciplinary approach combining organic chemistry, radiobiology, and molecular imaging, Professor Kabayama contributes to the advancement of targeted therapies and the fundamental understanding of complex disease mechanisms. His work positions him at the forefront of innovation in both therapeutic and diagnostic strategies in nuclear medicine.

host : Jean-Pierre POUGET (IRCM)

François LEULIER

Institut de Génomique Fonctionnelle de Lyon (IGFL), UMR 5242 CNRS / E.N.S. de Lyon (France)

"Microbial Influence on Juvenile Physiology"

hôte : Alexandre DJIANE et Jennifer FALCONI (IRCM-Inserm)

Professeur Bruno SEGUI

Centre de Recherche en Cancérologie de Toulouse (CRCT), UMR Inserm-CNRS-Toulouse University

"TNF blockade with certolizumab, but not infliximab, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma"

host: Laurent GROS (IRCM)

The combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However, 60% of patients fail to respond or relapse early after induction, and 95% develop immune-related adverse events (irAEs) such as colitis, which can be treated with infliximab, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL, NTC03293784). However, certolizumab, but not infliximab, strongly stimulates immune and therapeutic responses to ICI. Mechanistically, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy.

Yohei SHIMONO

Fujita Medical University

School of medecine, Department of Biochemistry, Nagoya (Japan)

"Vicious Adipocytes : promoters of cancer stem cell properties and tumor progression"

host : Andrei Turtoi (IRCM)

Géraldine GENTRIC

Equipe "Stress et Cancer"

Unité CHIP (U830) - Institut Curie-Paris

"Role of metabolic reprogramming in cell plasticity upon chemotherapy in ovarian cancers"

hôte : Julie Pannequin (IGF)